Background: Stathmin has been found to be involved in malignant tumors; the aim of this study was to investigate the relationship between serum stathmin and clinico-pathological features of lung cancer. Methods: In three lung cancer cell lines, stathmin expression and its secretion level in the supernatant were examined by Western blot and enzyme-linked immunosorbent assay (ELISA). Expression of stathmin was examined by immunohistochemistry in 48 lung cancer tissues, and serum stathmin expression level was examined by ELISA in 96 patients with lung cancer and 82 normal individuals. Sensitivity and specificity of serum stathmin were determined by receiver operator characteristic curve (ROC). Results: In the three cell lines and their supernatant, stathmin levels were higher than those in 16 HBE cell line. Lung cancer tissues expressed higher level stathmin more frequently than normal lung tissue (P < 0.05). Serum stathmin level was significantly higher in the patients with lung cancer than in normal individuals (P < 0.001). Increased stathmin level in cancer tissue and serum were significantly associated with adenocarcinoma histology, lymph node metastasis and advanced stage. The threshold level of serum stathmin for distinguishing lung cancer from normal individuals was 1.86 ng/ml. The sensitivity and specificity were 93.7% and 91.5%, respectively. Conclusions: Measurement of serum stathmin level could be a potential biomarker for lung cancer, especically those of adenocarcinoma, with lymph node metastasis and at advanced clinical stages.
Introduction
Lung cancer is one of the most common malignancies and is the leading cause of cancer-related deaths in China. This prognosis of lung cancer is dependent on the stage of the disease; however, confirming patients with lung cancer at early stage is a great challenge (1) . The identification of abnormal genes and proteins may be able to help find stable biomarkers that drive lung cancer development and progression, which may provide new strategy for early screening and diagnosis of malignant tumors; especially develop some new detecting strategy that can be detected by easily accessible samples, such as blood and sputum (2) . So far, mature serum biomarkers such as carcinoembryonic antigen (CEA) for adenocarcinoma, neuron-specific enolase (NSE) for small cell lung cancer (SCLC), CYFRA21-1 (cytokeratin 19 fragment) for squamous cell carcinoma (SCC) and squamous cell carcinoma antigen (SCCA) have been utilized for assisting diagnosis and monitoring treatment of patients with lung cancer (3) .
Stathmin (also known as Op18, p18, p19, stathmin 1 or metablastin) has been found to be up-regulated in some cancers and is correlated with cell differentiation and proliferation (4) (5) (6) (7) (8) (9) . In the previous study of proteomics, we found that in lung adenocarcinoma (LAC) PC-9 cell lines expression of stathmin was higher than in 16 HBE cell lines (human bronchial epithelial cells) (10) . Some researches show that stathmin regulates the cell apoptosis and motility, both in vitro and advanced, invasive and metastatic cancers in vivo (4, 5, (7) (8) (9) 11, 12) . However, compared with tissues and cells, investigating on the level of serum stathmin in patients with lung cancer is still lacking. In this research, we tested the expression level of stathmin in serum of patients with lung cancer, disclosed the relationship between serum stathmin and different clinical parameters of lung cancer and assessed its value in discerning lung cancer.
Material and methods
Involved cell lines and the condition of cell culture H446 cells (SCLC) and H520 cell lines (lung squamous cell carcinoma, LSCC) were presented from the Laboratory of Cell Molecular Biology, Lanzhou University, LanZhou, China. PC-9 cell line (human lung adenocarcinoma) was purchased from the Fuxiang Cell Biology Limited Company, Shanghai, China. Human 16 HBE (human bronchial epithelial) cell line was gotten from the Experimental Platform, Second Affiliated Hospital, Xi'an Medical University, Xi'an, China. We cultured these cells in an RPMI 1640 medium, which contained 10% FBS, penicillin (100 units/ml), and streptomycin (100 μg/ml, Invitrogen). The cells were cultivated in air incubator (5% CO 2 and 95%) at 37°C until using them.
Patient population
The study was approved by Research Ethics Committee of Gansu Provincial Hospital (Lanzhou, China) and First Hospital, Xi'an Medical University (Xi'an, China) respectively. All the patients signed the informed consent before including the study. From January 2014 to December 2015, a total 96 confirmed patients with lung cancer were recruited to participate the study (Gansu Provincial Hospital and First Hospital, Xi'an Medical University). The serum specimens of patients were gathered before receiving chemotherapy and surgery (Table 1) . Forty-eight of them underwent lung cancer resection finally, and then we collected the matched specimens from fresh lung cancer tissues and normal adjacent tissues. Over the same period, the serum samples of 82 healthy peoples (receiving strict physical examination) were gathered as serum normal control (63 ± 2.7 years) from the hospitals mentioned above. All patients were divided according to different clinical features (13) .
Immunohistochemistry (IHC)
The expression status of stathmin in lung cancer tissues was tested by IHC method (Kit of Ultra-sensitive S-P, Code: SP9000, produced by Zhongshan Jinqiao, Beijing, China), which was strictly performed according to a previous method that was described in published article (1) The best dilution of anti-human stathmin antibody is 1:200 (Code: ab47468, Abcam Company). The positive staining slice of breast cancer served as a positive control; PBS took place of the first antibody as the negative control. We invited two experienced pathologists (Wang JS and Zhang M) blindly evaluated the immunostaining of stathmin according to a previous method described (1) . For each section, ten high-magnification fields were randomly selected (>1000 cells) for calculating the expression scores, according to the area of staining and intensity of staining. The criterion of intensity: 0, no staining; 1+, mild staining; 2+, moderate staining; 3+, intense staining. The criterion of area: 0, no staining of cells in any microscopic fields; 1+, 30% of tissue stained positive; 2+, between 30% and 60% stained positive; 3+, >60% stained positive. The combined score (area of staining + intensity of staining) of ≤2 was considered as low expression, between 3 and 4 as moderate expression and between 5 and 6 served as high expression (1).
Western blot (WB) analysis
The concentration of protein from each sample was quantified via a method of Micro-BCA protein assay, and then proteins were loaded on SDS-PAGE gel and electrophoretically separated into polyvinylidene difluoride membranes. The polyvinylidene difluoride membranes were incubated with the first antibody of anti-human stathmin (1:500 dilution; Code: ab47468, Abcam Company) overnight at 4°C. Positive signal of stathmin expression was visualized using a method of enhanced chemiluminescence. β-Actin was tested synchronously as the internal control.
Enzyme-linked immunosorbent assay (ELISA)
The stathmin levels of serum and the supernatant of the cell lines were measured by ELISA Kit (Cloud-Clone Corp; Code: SEC892Hu) strictly following the testing procedures designed by the manufacturer. Serum samples and standard samples were diluted, respectively, and were added into the wells of reaction. The wells of reaction incubated for 2 h at a 37°C. After removed the liquid thoroughly, each well added 100 µl of reaction liquid A for 1 h at 37°C. Then, the wells were washed three times, and added 100 µl of reaction liquid B for 30 min at 37°C. After that, the wells were added lof substrate liquid at 37°C for 20 min in dark environment. The color biological reaction was duly terminated by 50 μl stopping solution and the intensity of color reaction was measured by a photometer at a wavelength of 450 nm. Standard curves were made according to the concentration of the standard sample and corresponding value of optical density of each well.
Chemiluminescent microparticle immunoassay (CMIA)
Serum CEA was determined using an automatic electrochemistry luminescence immunoassay system (ROCHE E170; Roche, Germany) at Department of Nuclear Medicine of Gansu Provincial Hospital, Lanzhou, China. The measurement of CEA was implemented following the procedure provided by the supplier. The cut-off value of CEA was 5.0 ng/ml, and the value was considered positive or negative for CEA if the level was above or below the value of 5.0 ng/ml.
Statistical analysis
The protein expression of stathmin in tissues was analyzed using the Chi-square test. The expression level of serum stathmin in different groups was compared using the Student's T-test (matched samples), One-WAY ANOVA (single factor analysis), Kruskal Wallis Test (nonparametric analysis) and non-parametric rank correlation analysis. The statistical analysis were finished with SPSS 19.0 (SPSS, Chicago, USA) software. The discernment of serum stathmin for discerning lung cancer was figured out using receiver operating characteristic (ROC) curves. When the P value was less than 0.05, we considered the statistical result had a significance of difference.
Results

Cultured human lung cancer cells displayed an increased stathmin
When used 16 HBE cell lines as a normal control, the expression level of stathmin in the PC-9, H520 and H446 cells was higher than in 16 HBE cell lines. Meanwhile, the stathmin expression of PC-9 cells was slightly higher than H446 and H520 cells, though the statistical results did not reach to a statistically significance (Fig. 1A, B) . Further, the stathmin levels in the supernatant of PC-9 (11.23 ± 2.56 ng/ml), H520 (10.34 ± 2.71 ng/ml), and H446 cell lines (8.59 ± 2.12 ng/ml) were higher than that in 16 HBE cell lines (3.71 ± 1.29 ng/ml) (P < 0.05), but there was no obvious difference between three lung cancer cell lines.
Tissues with lung cancer showed an increased expression of stathmin compared with adjacent normal tissues
We performed a test of IHC for stathmin in a series of 48 lung cancer tissues from the patients who underwent surgical resection; the positive expression of stathmin was located in cellular protoplasm of cells and colored brown (Fig. 1C-H ). The expression of stathmin was higher in tissues with lung cancer (24/48, 50%) than in normal tissues (8/48,16.7%) (P < 0.05; Table 2 ).
Increased stathmin of lung cancer tissues correlated with clinicopathologic factors of lung cancer
Stathmin was highly expressed in LAC (18/26, 69.2%), compared with LSCC (6/22, 27.3%) (P < 0.05). Lung cancer tissues with lymph node metastasis (16/26, 61.5%) showed a higher expression of stathmin than those of without lymph node metastasis (8/22, 36.4%) (P < 0.05). And increase of stathmin was displayed in tissues with lung cancer at stages III-IV (20/28, 71.4%), compared with those of stages I-II (4/20, 20%) (P < 0.05) ( Table 2 , Fig. 1I-L) .
Lung cancer patients presented a higher level of serum stathmin than normal individuals Serum level of stathmin was detected by a method of ELISA. The results indicated that expression level of serum stathmin was higher in patients with lung cancer (6.32 ± 1.30 ng/ml) than in normal individuals (1.04 ± 0.12 ng/ml) (P < 0.001) ( Table 3 , Fig. 2A ). Increased serum stathmin correlated with clinicopathologic factors of lung cancer patients LAC patients (7.06 ± 0.92 ng/ml) revealed a higher level of serum stathmin than those with LSCC (4.85 ± 1.26 ng/ml) and SCLC (5.05 ± 0.1.9 ng/ml) (P < 0.05). Patients with lymph node metastasis (N1-N2, 6.53 ± 1.93 ng/ml; N3, 6.87 ± 0.65 ng/ml) exhibited an increased level of serum stathmin than those without lymph node metastasis (5.90 ± 1.42 ng/ml) (P < 0.05). Lung cancer patients at III-IV stage (6.67 ± 0.84 ng/ml) showed a higher serum stathmin than those of I-II stage (5.76 ± 1.73 ng/ml) (P < 0.05). The serum level of stathmin did not correlate with pathologic grade and pleural invasion of lung cancer (P > 0.05) ( Table 3 , Fig. 2B-F) .
Expression of stathmin in tissues and serum specimens displayed a similar trend
To verify whether the stathmin expression in lung cancer tissues is consistent with serum of patients, we performed a non-parametric rank correlation analysis for the expression of stathmin in matched 48 tissues and serum specimens. Serum detection value of stathmin is divided into three zones, which corresponded to the three levels of tissues detection. Statistical results showed that the spearman rank correlation coefficient is 0.786, P = 0.032. According to the significance level of a = 0.05, rejected null hypothesis, suggesting that expression of stathmin in tissues and serum had a certain positive correlation.
Threshold value of serum stathmin for discerning patients with lung cancer from normal individuals
The cut-off value of serum stathmin for discerning patients with lung cancer was determined via ROC curve analysis (14) . The minimum serum value of stathmin was 0.138 ng/ml, which was observed in the normal control group while the maximum was 16.2 ng/ml, located in the disease group with lung cancer. It showed that the threshold of serum stathmin discerning lung cancer from normal individuals intersected near the zones of 1.5-3 ng/ml, meanwhile 95% confidence interval (CI) was from 0.441 to 6.618 (Table 4 , Fig. 3A ).
Accuracy of serum stathmin for discerning lung cancer
The threshold of stathmin for distinguishing lung cancer patients from normal people was defined as 1.86 ng/ml, responding a sensitivity of 93.75% and specificity of 91.46% (Table 4) . In order to discern lung cancer, the AUC (area under the curve) of stathmin arrived at 0.967 with 0.0131 of standard error, while 95% CI was from 0.928 to 0.988, and then Z value was 35.658 (P < 0.001) (Fig. 3B) .
Comparison of diagnosis value for lung adenocarcinoma between serum stathmin and CEA Serum CEA was detected using a method of chemiluminescence and showed that in lung adenocarcinoma patients the serum CEA revealed an increased expression (17.1 ± 4.3 ng/ml), compared with healthy examined peoples (0.68 ± 0.19 ng/ml) (P < 0.001) (Fig. 3C ). Linear correlation model indicated there was strongly linear correlation between CEA and stathmin, which showed that the correlation coefficient of regression model was 0.5211 (95% confidence interval: 0.3730-0.6434) (P < 0.001; Fig. 3D ). When comparing stathmin with CEA for discerning lung adenocarcinoma patients from normal individuals, the difference between AUC just was 0.0387 (Z value = 1.556; P = 0.156) (Fig. 3E) . Combining both markers yielded specificity for distinguishing lung adenocarcinoma from benign lung disease of 98%, with a sensitivity of 92%. With healthy individuals used as the controls, the sensitivity and specificity of CEA and stathmin had an equal efficacy, and the Yonden index was symmetrically close to one (Fig. 3F ).
Discussion
Circulating proteins in peripheral blood have been investigated as a significant resource for measuring various cancer biomarkers because of high stability of expression, intimate relationships with cancer states, and sensitive measurement. Nowadays, a series of biomarkers have been recommended to diagnose and manage those patients with lung cancer, including CEA, NSE, CYFRA21-1 and SCCA (15, 16) . Since cancer biomarker discovery has started extensively with the progress of proteomic technology, many protein molecules have been indicated as potential cancer biomarkers (17) . Nevertheless, very effective marker for distinguishing lung cancer in clinical practice is quite absent. Stathmin, a 19-kDa soluble phosphoprotein, is up-regulated in some cancers and related to cell differentiation and proliferation (4, 5, 7, 8, 12, 18) . Some studies showed that stathmin over-expression is markedly correlated with the tumorigenesis, progression and prognosis of tumors (4) (5) (6) (7) (8) (9) 11, 12, 18) . To disclose the epidemiologic features of stathmin in lung cancer and its clinicopathological significance, we detected the serum stathmin of lung cancer patients and disclosed its relationships with clinicopathological factors. We found that in all three lung cancer cell lines (PC-9, H520 and H446 cell lines) stathmin was generally up-regulated, when compared with the 16 HBE cell line, which displayed a consistent trend and results with previously investigations (4, 5) . We also found stathmin protein was highly expressed in lung cancer tissues with different histological types, especially in LAC. Meanwhile we further observed that increased stathmin was intimately involved in lymph node metastasis of lung cancer and high TNM stage. Thus, this gave us a clue that increased stathmin expression is possibly involved in carcinogenesis and progression of lung cancer. The suggestion from our study is in accordance with previously published investigations, where an upregulated level of stathmin in malignant tumors is associated with unfavorable outcomes, as compared with cancer patients with low expression levels of stathmin (4, 8) , suggesting that increased expression of stathmin contributes to the progression and metastasis of cancer. The phenomena on lung cancer tissues strongly strengthened the evidence of increased expression of stathmin in various lung cancer cells. It is a clear conclusion that the intensity of evidence in both of cells and tissues far outweigh the evidence from each of them. Combined examination of both may provide a solid result than single one of them and promote the accuracy of stathmin as a biomarker.
Up to now, a series of biomarkers for discerning lung cancer and monitoring progress have been detected in serum, such as CEA, CYFRA21-1, NSE, and so on (19, 20) . Serum biomarkers predicting patient prognosis or response to therapy may make progress in the potential of personalized medicine in cancer treatment. Previous studies have evaluated the correlation between stathmin and patient clinicopathological features (6) (7) (8) 11) . Nevertheless, the expression feature of serum stathmin in patients with lung cancer is hardly investigated so far. In our study, the serum stathmin showed a significantly increase in lung cancer patients, as compared with those who had suffered from lung cancer, thus suggesting a marked correlation between the up-regulation of stathmin level and an upward risk of lung cancer. Besides, lung cancer with the increased stathmin level in serum of lung cancer patients seems to be showed a malignant phenotype being indicated by lymph node metastasis, poorly differentiated tissues and advanced stage of lung cancer patients. These results are more likely to propose a strategy that the level of serum stathmin could serve as a predictive factor for emergence of lung cancer and promise a new tool for diagnosing lung cancer.
When we discern lung cancer patients from normal people, stathmin showed an ideal discriminating ability with a sensitivity of 93.75% and specificity of 91.46%, suggesting it is more likely to be a biomarker for lung cancer diagnosis. When calculating the cut-off value of stathmin using the ROC analysis, it corresponded a threshold of 1.86 ng/ml for discerning the lung cancer patients from normal individuals, thus showing stathmin not only can be use to differentiate lung cancer, but also to screen early lung cancer. Because CEA is very effective biomarker for lung adenocarcinoma, so we used it as confrontation to compare the sensitivity and specificity of serum stathmin. Using the threshold of 1.86 ng/ml, we found the sensitivity and specificity of serum stathmin equaled about those of CEA. Taking those findings together, we deduced that serum stathmin had a potential to become a useful marker for lung adenocarcinoma and may contribute to early diagnosis of lung cancer. A number of studies are concordant with the notion that stathmin expression is upregulated in a variety of human cancers (4) (5) (6) (7) (8) 11) , and may be served as effective prognostic and diagnostic indicators for cancer patients. However, there are still many works before serum stathmin could be used to conduct the diagnosis and treatment of lung cancer in clinical practice.
There are several limitations in this study. First, it was carried out in two research institutes in China, which may not represent the feature of the wider population. Second, the study did not (E) When stathmin is compared with CEA for differentiating lung adenocarcinoma patients from healthy donors, the difference between AUC was 0.0387, no statistics significance (P = 0.156). (F) the sensitivity and specificity of two markers have almost equal efficacy, and the Yonden index was symmetrically close to 1; CEA, carcinoembryonic antigen; ROC, receiver operating characteristic curve. sufficiently assess difference of stathmin level between lung cancers at early stages (I-II stage). Therefore, further investigations designing larger samples of patients with lung cancer are still required to get more solid and reliable conclusion.
Conclusion
The expression of stathmin was up-regulated in both cancer tissues and serum of lung cancer patients, especially in lung adenocarcinoma, which indicated that stathmin is potentially involved in the tumorigenesis, development and metastasis of lung adenocarcinoma. And the serum stathmin could serve as a potential biomarker for discerning lung cancer patients from those with non-malignant disorders.
Declarations Ethics
This study was approved by Research Ethics Committee of Gansu Provincial Hospital (Lanzhou, China) and First Affiliated Hospital of Xi'an Medical University (Xi'an, China), respectively. We obtained written and informed consent individually from all the patients.
Consent to publish
Not applicable.
Authors' contributions
Rong Biaoxue and Gao Wenlong completed the literature search, data collection, data analysis, data interpretation, and drafted the first version of the manuscript. Liu Hua and Fu Tian contributed to study design, data interpretation, and experimental operation.
Availability of data and materials
The datasets supporting the conclusions of this article are included within the article.
Data deposition
Funding
This study received funding from Technology Research and Development Plan of Gansu Province (0912TCYA016).
